We herein report the first case of a nonfunctioning islet cell tumor that transformed into a proinsulinoma during the process of metastasis to the lungs. This phenomenon was confirmed in a 69-year-old woman with an advanced pancreatic islet cell tumor and multiple liver metastases who later developed multiple lung metastases. She underwent pancreatic resection followed by the administration of chemotherapy and survived for seven years. Although the patient initially had hyperglycemia due to diabetes mellitus, she conversely began to manifest hypoglycemic attacks 63 months postoperatively with the concomitant development of multiple lung metastases. An autopsy revealed that only the tumor in the lungs produced proinsulin; no other hormones were detected.
Introduction
Proinsulin is a chemical precursor of insulin produced by β-cells in the islets of the pancreas. The hypoglycemic activity of proinsulin has been estimated to be only approximately 10% of that of insulin, although this prohormone may cause hypoglycemia similar to insulin. Proinsulinsecreting islet cell tumors of the pancreas, which manifest with the clinical symptoms of hypoglycemia -so called "proinsulinomas" -are extremely rare tumors. Nonfunctioning islet cell tumors of the pancreas are masses that exhibit neuroendocrine differentiation in the absence of a clinical syndrome. Usually, nonfunctioning islet cell tumors maintain their nature, even after they metastasize to other organs or grow very large in size. For example, metastatic insulinomas secrete insulin, causing hypoglycemia, whereas metastases originating from nonfunctioning islet cell tumors usually do not secret any hormones, in concordance with the original pancreatic tumors.
We herein report the first case of a nonfunctioning islet cell tumor that transformed into a proinsulinoma during the process of metastasis to the lungs. vealed the tumor to be a neuroendocrine tumor (NET). The tumor cells contained round nuclei and exhibited a trabecular or nesting growth pattern ( Fig. 2A) as well as positive immunoreactivity to chromogranin A (Fig. 2B) . However, glucagon, insulin and gastrin were all immunohistochemically negative (Fig. 2C-E) . Although the tumor was very aggressive, invading the surrounding organs and metastasizing to the liver, it was classified as NET G1 according to the WHO classification 2010 because the Ki67 labeling index was only 1% (Fig. 2F) . In terms of the therapeutic strategy for this patient, we contemplated whether we would be able to successfully resect the original pancreatic tumor with the invaded organs en bloc, with the administration of chemotherapy or transarterial chemoembolization (TACE) for the multiple liver metastases, to improve the patient's survival. In order to evaluate the effects of chemotherapy in advance of performing surgery, we first administered hepatic arterial infusion chemotherapy in the whole liver. The patient was subsequently treated with mitomycin-C in combination with 5-fluorouracil (5-FU) (see Table 2 in detail). After three courses of chemotherapy (three months), CT revealed that the hepatic tumors had either remained stable or slightly decreased in size, whereas the original pancreatic tumor had enlarged. We therefore performed distal pancreatectomy combined with total gastrectomy, transverse colectomy and left nephrectomy. Although the arterial infusion chemotherapy using mitomycin-C with 5-FU was restarted postoperatively and continued for five courses (five months), the multiple liver metastases gradually increased in size. Therefore, we changed the regimen from mitomycin-C with 5-FU to cisplatin with 5-FU (Table 2) ; however, this regimen was not effective, and gemcitabine was finally administered systemically (Table 2 ). In spite of decreasing the dose of gemcitabine due to nausea and appetite loss, the hepatic tumors were stably controlled for 24 months until they began to again become enlarged. TACE was then performed using epirubicin (20 mg) and lipiodol; this regimen was repeated five times every four months, and the hepatic tumors were again well controlled for another 20 months.
Postoperatively, the patient's insulin requirement was transiently increased from 15 units/day to 22 units/day. However, starting approximately 34 months after surgery, the need for insulin began to decrease gradually, rapidly disappearing after 61 months postoperatively (Fig. 3) . Two months later, she experienced an attack of unconsciousness with hypoglycemia (blood sugar: 24 mg/dL). At that time, the serum insulin level was 15.7 μU/mL (reference range: 1.1-17.0 μU/mL) and the C-peptide level was 2.27 ng/mL (reference range: 1.1-3.3 ng/mL). We strongly suspected that the patient had developed an insulinoma because the insulin level seemed to be too high -although it was within the reference range -relative to the very low serum sugar level of 24 mg/dL, suggesting evasion of feedback mechanisms. Indeed, Fajans' index (immunoreactive insulin/blood glucose) was calculated to be 0.65 (reference range: below 0.30). However, we were unable to detect the focus of the insulinoma. One month after the hypoglycemic attack, multiple 60 mg/body (every day, 2 weeks) Oral followed by 1 week rest FU: fluorouracil, HAI: hepatic arterial infusion, S-1: an oral fluoropyrimidine, mo: months metastases appeared in the bilateral lungs (Fig. 4) . We subsequently administered sandostatin under a protocol of 100 μg/day for 20 days; however, hypoglycemic attacks repeatedly occurred. We next tried diazoxide at a dose of 100 mg/ day for the first two days and 200 mg/day for the next two days; however, the hypoglycemia did not improve and highcaloric infusion therapy was required to maintain a normal blood sugar level. The patient was then treated with gemcitabine in combination with S-1, a novel oral fluoropyrimidine (Table 2) for three months. Nevertheless, the tumors further enlarged, and, seven years after the initiation of the first chemotherapy regimen, she died of disease progression. An autopsy revealed immunoreactivity for insulin in the lung metastases to be negative, whereas that for proinsulin was strongly positive. Interestingly, the hepatic metastases in the autopsy specimen and the original pancreatic tumor in the operative specimen were both negative for either proinsulin or insulin (Fig. 5) . Parenthetically, the Ki67 labeling indices of the metastatic lesions also remained as low as below 1% in spite of the highly malignant nature of these tumors to develop distant metastases. Based on these findings, we concluded that the nonfunctioning islet cell tumor of the pancreas had transformed into a proinsulinoma during the process of metastasis to the lungs and subsequently caused a shift from diabetes mellitus to hypoglycemia in this patient.
Discussion
Pancreatic neuroendocrine tumors (pNETs) are rare, accounting for less than 5% of all pancreatic malignant tumors (1, 2). These tumors can be classified into two types: "functioning tumors with clinical symptoms" and "nonfunctioning tumors" (2-4). Only 25% of pNETs are nonfunctioning (5). Among functioning pNETs, insulinomas are the most common type, with insulin hypersecretion causing hypoglycemia, which can occasionally lead to a hypoglycemic coma.
Proinsulin is a precursor of insulin, the residue of which is the C-peptide. Proinsulin is usually stored in the insulin granules present in β-cells. Approximately 90% of proinsulin is decomposed in insulin granules, while only 10% is released into the blood as intact proinsulin. Bioactive proinsulin, which lowers the blood sugar level, comprises only 10% of insulin. However, the proinsulin continuously produced by a proinsulinoma is thought to play a role similar to the insulin produced by an insulinoma. Tumors that secrete proinsulin alone, such as that observed in our patient, are very rare (6) (7) (8) (9) (10) . In the present case, the immunohistochemical examination did not confirm the production of insulin by the tumors, including the original tumor as well as the liver and lung metastases. However, the relatively high serum insulin concentration obtained on the laboratory examination performed at the time of the patient's hypoglycemic attack primarily suggested the hyperproduction of insulin. This discrepancy may be derived from the effects of the insulin measurement kit used in this case [ST AIA-PACK IRI insulin kit (TOSOH, Tokyo, Japan)]. The anti-insulin antibody contained in this kit exhibits 2% cross-reactivity to human proinsulin (manufacturer's data). It is likely that the kit misidentified proinsulin as insulin, although the serum insulin level was not elevated. Nonfunctioning islet cell tumors may be identified based on the following characteristics: the tumor does not produce any hormones; the tumor produces hormones but does not secrete these hormones excessively; or the tumor does not present with any clinical symptoms. "Nonfunctioningness" is confirmed according to the lack of elevation of serum hormones and/or immunoreactivity in the pathological specimens. In the present case, no immunoreactivity for hormonal antigens was detected in the specimen of the liver metastases. The patient had required insulin for diabetes mellitus while the tumor remained nonfunctioning. However, after the tumor transformed into a functional one, she no longer exhibited a demand for insulin and ultimately developed hypoglycemia instead of hyperglycemia. There are no previous reports of a proinsulinoma transforming from a nonfunctioning islet cell tumor. Vashi et al. reported a case of an insulinoma that transformed from a nonfunctioning islet cell tumor with multiple liver metastases; this is the only published case report describing the transformation of a tumor from a nonfunctioning islet cell tumor (11) . In that report, the diagnosis of the nonfunctioning islet cell tumor was made only by examining the serum hormonal levels. Unfortunately, the authors did not describe the histological confirmation of the produced hormones. They diagnosed the tumor as an insulinoma that had transformed from a nonfunctioning islet cell tumor because the patient, who initially required insulin for diabetes mellitus subsequently developed hypoglycemia with hyperinsulinemia. The researchers supposed that this phenomenon may either occur during the course of treatment or due to the growth of the tumor. Therefore, they described the tumor as an "insulin secretory tumor transformed from a nonsecretory endocrine tumor." In contrast, the original pancreatic tumor in the present case did not produce any hormones, as confirmed immunohistochemically in the operative specimen. Only the lung metastasis produced proinsulin, and the metastatic tumors in the liver remained nonfunctioning until the patient's death. These findings were confirmed on the autopsy specimens, which showed that the tumors did not change into proinsulinomas, even while the lung metastases transformed into proinsulinomas. We suppose that this unique phenomenon may have resulted from the different circumstances in the liver and lungs, rather than the effects of the multidisciplinary therapy.
In conclusion, we herein described the first case of a nonfunctioning islet cell tumor that transformed into a proinsulinoma during the process of metastasis to the lungs. This case suggests that nonfunctioning islet cells have the potential for pluripotent differentiation to other hormoneproducing cells.
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